Lumigan (Bimatoprost) Patent Expiration, LOE Window & CMS Spending
Lumigan (Bimatoprost) by AbbVie: FDA Orange Book core substance LOE 2027-06-13, 2 AB generics, $665.4M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N022184 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-06-13 |
| Last Listed Patent or Exclusivity Date | 2027-06-13 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $665.4M |
| 2024 Medicare Part D Spend | $647.2M |
| 2024 Medicaid Spend | $18.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.